Lei Lei Wu

RT @maxonwifi: "A person who was briefed on the meeting said Kennedy didn’t want to turn stem cell regulation into the 'Wild West.'" Grea…

HHS Secretary Robert F. Kennedy Jr. and his staff last Wednesday hosted a regenerative medicine roundtable primarily to discuss how to lower regulatory barriers for stem cell treatments My story in @endpts: https://t.co/HkLXMlfyCY

RT @ZacharyBrennan: Scoop: Trump admin reverses course on FDA drug quality lab lease termination - https://t.co/7Iq03jgYXx

RT @ZacharyBrennan: DOGE cuts the lease on FDA's 52k sq-ft St. Louis pharma quality lab - unclear if the 70 scientists will be cut. One wor…

RT @SarahKarlin: Breaking: FDA's March meeting to select flu shot strains for 2025-2026 season has been canceled per email sent to committe…

RT @JohnCendpts: I find these small cancer trials really intriguing, because you can tease out activity without blowing the bankroll. So wh…

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma https://t.co/pqP1aJyTzO

RT @ArmstrongDrew: Ex-CDER chief Cavazzoni is going to Pfizer, according to an internal announcement: https://t.co/YuckOKk5rx

RT @ZacharyBrennan: Round 2 of drug price negotiations is up - and the GLP-1s ARE included https://t.co/SbtEx1M1fq

Had the honor of interviewing two incredible women this week. Thanks Janet Woodcock and Jennifer Doudna for joining me on stage! https://t.co/xRmhmmZyN6

RT @HmpxvT: ⚠️BREAKING: H5N1 bird flu has been found in a pig in Oregon, USDA reports.

I wrote in @endpts about the Human Tumor Atlas Network - a project from Biden's Cancer Moonshot to make 3D maps that can help scientists study the earliest stages of cancer, which have not been well-explored ft. @WUSTLnews @KenLauLab @SnyderShot and more https://t.co/JqJasEQych

Revolution Medicines breaks ground in challenging pancreatic cancer with two RAS drugs https://t.co/gHY9hO2HXa

For NYC folks -- I'm moderating a convo next week at BioFuture about emerging approaches in cell & gene therapy for the second year in a row https://t.co/F3TNjxIfTS

Precision Biosciences has received clearance from regulators in the Eastern European country of Moldova to begin a human trial of a gene editor for chronic hepatitis B, marking the first such test in the world. $DTIL https://t.co/SAnE0E4uSD

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers https://t.co/8ZPs9QSZ7R

interesting — Sangamo had stopped investing in its Fabry gene therapy last year to cut costs + could/would not fund a Phase 3 study now its saying FDA has agreed to accelerated approval pathway with no confirmatory trial needed from @MaxGelman https://t.co/jdU3ed4LGy